Industry Insight
By
Jun 16, 2026
Case study:
A self-funded plan sponsor faced rising pharmacy costs and lacked data transparency to manage spend effectively.
Background
When a self‑funded plan sponsor struggled to manage rising pharmacy spend and lacked the data transparency needed to make informed decisions, switching to Scripius delivered meaningful savings, reducing total drug spend by one‑third in the first year.
Approach
- Removed low-value drugs and guided members to lower net cost alternatives to achieve clinical optimization
- Delivered cost certainty with a guaranteed PMPM, backed by real financial accountability from Scripius
- Employed a rapid onboarding strategy coupled with a two month grace period to smooth the transition for plan members
Result
The client achieved significant cost savings with minimal disruption.
Discover how transparent cost savings strategies can deliver measurable savings for you. Connect with your pharmacy benefits consultant or contact us.
Visit: scripius.org | Email: maketheswitch@scripius.org
Reducing diabetes drug cost
Reducing diabetes drug cost trend growth by ~40% with a lowest net cost approach
Read more
Advancing inflammatory biosimilars
How Scripius uses biosimilar adoption as part of its lowest net cost strategy
Read more
Biosimilar savings
Scripius is poised to make a decisive move by removing Stelara from our standard Large Employer formularies as of July 1, 2025.
Read more